A study led by Associate Professor Morten Scheibye-Knudsen indicates that targeting the plk1 gene may offer a promising treatment for sarcoma patients who exhibit high levels of the cep135 protein. Sarcomas, accounting for only 1% of all cancer cases, are complex tumors originating in bones and soft tissues, with a challenging prognosis. The research identified a method to stratify sarcoma patients, potentially allowing for tailored treatments depending on cancer cell biology. The study revealed that high cep135 protein levels correlate with poor outcomes; however, inhibiting the plk1 gene could suppress sarcoma cell growth, suggesting a new therapeutic direction. The researchers emphasized the importance of personalized treatment, as no two cancers are alike, and proposed that results from this study could lead to new therapies within 5-10 years. The investigation began by studying patients with rare premature aging syndromes, where they found that gene expression related to cep135 is common in various cancers, including sarcoma. Ultimately, the methodology used could be applicable to other age-related diseases, extending the potential impact beyond sarcoma treatment. The findings advance the understanding of cancer biology in relation to genetic disorders associated with aging.
